The relationship between Human Immunodeficiency Virus (HIV) and Helicobacter pylori (H. pylori) is bidirectional and complex. Helicobacter pylori, by inducing local gastric and systemic immune responses, counteracts HIV invasion to CD4+ cells and other inflammatory cells and can reactivate HIV in latently infected immune cells. Human Immunodeficiency Virus infection, by reducing secretion of pro-inflammatory cytokines, reduces the incidence of H. pylori-induced gastric pathology. Gastric lymphoma regressed in some cases of people living with HIV (PLWH) after H. pylori eradication. Triple therapy for H. pylori could be associated with a strong immune. Treatment for both H. pylori and HIV can reduce the activation of either organism. However, the primary resistance to antibiotics such as levofloxacin, clarithromycin and metronidazole is higher among PLWH. This review highlights the need for further research and guidelines on the appropriate antibiotics in HIV–H. pylori co-infection particularly in PLWH who receive multiple antibiotic prophylaxis.
BlaserMJ. Helicobacter pylori: its role in disease. Clin Infect Dis1992; 15: 386–391.
2.
RothenbacherDInceogluJBodeG, et al.Acquisition of Helicobacter pylori infection in a high-risk population occurs within the first 2 years of life. J Pediatr2000; 136: 744–748.
3.
MoayyediPAxonATFeltbowerR, et al.Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int J Epidemiol2002; 31: 624–631.
4.
MalcolmCMacKayWShepherdA, et al.Helicobacter pylori in children is strongly associated with poverty. Scott Med J2004; 49: 136–138.
5.
BauerSKrumbiegelPRichterM, et al.Influence of sociodemographic factors on Helicobacter pylori prevalence variability among schoolchildren in Leipzig, Germany. A long-term follow-up study. Cent Eur J Public Health2011; 19: 42.
6.
RomanelliFSmithKMMurphyBS. Does HIV infection alter the incidence or pathology of Helicobacter pylori infection?AIDS Patient Care STDS2007; 21: 908–919.
7.
NevinDTMorganCJGrahamDY, et al.Helicobacter pylori gastritis in HIV-infected patients: a review. Helicobacter2014; 19: 323–329.
8.
VairaDMiglioliMMenegattiM, et al.Helicobacter pylori status, endoscopic findings, and serology in HIV-1-positive patients. Dig Dis Sci1995; 40: 1622–1626.
9.
CacciarelliAGMarano JrBJGualtieriNM, et al.Lower Helicobacter pylori infection and peptic ulcer disease prevalence in patients with AIDS and suppressed CD4 counts. Am J Gastroenterol1996;91: 1783–1784.
10.
MohamedFALuleGNyong’oA, et al.Prevalence of Helicobacter pylori and endoscopic findings in HIV seropositive patients with upper gastrointestinal tract symptoms at Kenyatta National Hospital, Nairobi. East Afr Med J2002; 79: 226–231.
11.
LvF-JLuoX-LMengX, et al.A low prevalence of H pylori and endoscopic findings in HIV-positive Chinese patients with gastrointestinal symptoms. World J Gastroenterol2007; 13: 5492.
12.
FialhoABBraga-NetoMBGuerraEJ, et al.Low prevalence of H. pylori infection in HIV-positive patients in the northeast of Brazil. BMC Gastroenterol2011; 11: 1–5.
13.
KafilHSJahromiFFHajikhaniB, et al.Screening for the presence of Helicobacter pylori in stool of HIV-positive patients. J AIDS HIV Res2011; 3: 85–87.
14.
NkuizeMDe WitSMulsV, et al.Comparison of demographic characteristics and upper gastrointestinal endoscopy findings in HIV-positive, antiretroviral-treated patients with and without Helicobacter pylori coinfection. Helicobacter2012; 17: 153–159.
15.
DeyiVMVanderpasJBontemsP, et al.Marching cohort of Helicobacter pylori infection over two decades (1988–2007): combined effects of secular trend and population migration. Epidemiol Infect2011; 139: 572–580.
16.
Pa Pa AungWMyintNZawTT, et al.The influence of HIV status on the burden and clinical manifestations of gastrointestinal pathogens in Yangon, Myanmar. Am J Trop Med Hyg2020; 102: 884–888.
17.
BenzJHasbachHBrendenM, et al.Humoral and cellular immunity in HIV positive and HIV negative Helicobacter pylori infected patients. Zentralbl Bakteriol1993; 280: 186–196.
18.
EdwardsPDCarrickJTurnerJ, et al.Helicobacter pylori-associated gastritis is rare in AIDS: antibiotic effect or a consequence of immunodeficiency?Am J Gastroenterol1991; 86: 1761–1764.
19.
LopetusoLRScaldaferriFFranceschiF, et al.The gastrointestinal microbiome–functional interference between stomach and intestine. Best Pract Res Clin Gastroenterol2014; 28: 995–1002.
20.
GollRGruberFOlsenT, et al.Helicobacter pylori stimulates a mixed adaptive immune response with a strong T-regulatory component in human gastric mucosa. Helicobacter2007; 12: 185–192.
21.
MitchellPGermainCFioriPL, et al.Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development. Infect Immun2007; 75: 810–819.
22.
KhamriWWalkerMMClarkP, et al.Helicobacter pylori stimulates dendritic cells to induce interleukin-17 expression from CD4+ T lymphocytes. Infect Immun2010; 78: 845–853.
23.
ArnoldICHitzlerIMüllerA. The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol2012; 2: 10.
24.
BrenchleyJMPriceDASchackerTW, et al.Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med2006; 12: 1365–1371.
25.
EmuBMorettoWJHohR, et al.Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. PLoS One2014; 9: e85613.
26.
Serrano-VillarSSainzTLeeSA, et al.HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog2014; 10: e1004078.
27.
BoncristianoMPaccaniSRBaroneS, et al.The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med2003; 198: 1887–1897.
28.
TorresVJVanCompernolleSESundrudMS, et al.Helicobacter pylori vacuolating cytotoxin inhibits activation-induced proliferation of human T and B lymphocyte subsets. J Immunol2007; 179: 5433–5440.
29.
LinaTTPinchukIVHouseJ, et al.CagA-dependent downregulation of B7-H2 expression on gastric mucosa and inhibition of Th17 responses during Helicobacter pylori infection. J Immunol2013; 191: 3838–3846.
30.
LinaTTAlzahraniSGonzalezJ, et al.Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol2014; 20: 12753–12766.
31.
GebertBFischerWWeissE, et al.Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science2003; 301: 1099–1102.
32.
CoverTLBlankeSR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol2005; 3: 320–332.
33.
Oswald-RichterKTorresVJSundrudMS, et al.Helicobacter pylori VacA toxin inhibits human immunodeficiency virus infection of primary human T cells. J Virol2006; 80: 11767–11775.
34.
ShiraiMFujinagaRMasakiT, et al.Impaired development of HIV-1 gp160-specific CD8(+) cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with Helicobacter pylori infection. Eur J Immunol2001; 31: 516–526.
35.
KaoJYZhangMMillerMJ, et al.Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology2010; 138: 1046–1054.
36.
LundinBSEnarssonKKindlundB, et al.The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol2007; 125: 205–213.
37.
EberhardtKASarfoFSDomprehA, et al.Helicobacter pylori coinfection is associated with decreased markers of immune activation in ART-naive HIV-positive and in HIV-negative individuals in Ghana. Clin Infect Dis2015; 61: 1615–1623.
38.
AbadiTTekluTWondmagegnT, et al.CD4(+) T cell count and HIV-1 viral load dynamics positively impacted by H. pylori infection in HIV-positive patients regardless of ART status in a high-burden setting. Eur J Med Res2024; 29: 178.
39.
KirschnerDEBlaserMJ. The dynamics of Helicobacter pylori infection of the human stomach. J Theor Biol1995; 176: 281–290.
40.
NatarajanVMoarPKaurUS, et al.Helicobacter pylori reactivates human immunodeficiency virus-1 in latently infected monocytes with increased expression of IL-1β and CXCL8. Curr Genomics2019; 20: 556–568.
41.
OrensteinJMFoxCWahlSM. Macrophages as a source of HIV during opportunistic infections. Science1997; 276: 1857–1861.
42.
AgaceWWRobertsAIWuL, et al.Human intestinal lamina propria and intraepithelial lymphocytes express receptors specific for chemokines induced by inflammation. Eur J Immunol2000; 30: 819–826.
43.
IellemAMarianiMLangR, et al.Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med2001; 194: 847–853.
44.
StrömbergELundgrenAEdeboA, et al.Increased frequency of activated T-cells in the Helicobacter pylori-infected antrum and duodenum. FEMS Immunol Med Microbiol2003; 36: 159–168.
45.
ChunTWCarruthLFinziD, et al.Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature1997; 387: 183–188.
46.
FabrisPPilottoABozzolaL, et al.Serum pepsinogen and gastrin levels in HIV-positive patients: relationship with CD4 + cell count and Helicobacter pylori infection. Aliment Pharmacol Ther2002; 16: 807–811.
47.
MagenEElbirtDAgmon-LevinN, et al.Eradication of Helicobacter pylori can facilitate immune reconstitution in HIV-1-infected immunological non-responders. Int J Infect Dis2010; 14: e322–e327.
48.
ClericiMShearerGM. The Th1–Th2 hypothesis of HIV infection: new insights. Immunol Today1994; 15: 575–581.
49.
KaurRDhakadMGoalR, et al.Study of TH1/TH2 cytokine profiles in HIV/AIDS patients in a tertiary care hospital India. J Med Microbiol Diagn2016; 5: 2161–0703. 1000214.
50.
PrendergastAPradoJGKangY-H, et al.HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS2010; 24: 491–502.
51.
BhuiyanTRIslamMMTUddinT, et al.Th1 and Th17 responses to Helicobacter pylori in Bangladeshi infants, children and adults. PLoS One2014; 9: e93943.
52.
ShiYLiuX-FZhuangY, et al.Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. J Immunol2010; 184: 5121–5129.
53.
BagheriNRazaviAPourgheysariB, et al.Up-regulated Th17 cell function is associated with increased peptic ulcer disease in Helicobacter pylori-infection. Infect Genet Evol2018; 60: 117–125.
54.
HorvathDJJrWashingtonMKCopeVA, et al.IL-23 contributes to control of chronic Helicobacter pylori infection and the development of T helper responses in a mouse model. Front Immunol2012; 3: 56.
55.
GrayBMFontaineCAPoeSA, et al.Complex T cell interactions contribute to Helicobacter pylori gastritis in mice. Infect Immun2013; 81: 740–752.
56.
AdamssonJOttsjöLSLundinSB, et al.Gastric expression of IL-17A and IFNγ in Helicobacter pylori infected individuals is related to symptoms. Cytokine2017; 99: 30–34.
57.
BagheriNShirzadHElahiS, et al.Downregulated regulatory T cell function is associated with increased peptic ulcer in Helicobacter pylori-infection. Microb Pathog2017; 110: 165–175.
58.
KrzyżekPGościniakG. A proposed role for diffusible signal factors in the biofilm formation and morphological transformation of Helicobacter pylori. Turk J Gastroenterol2018; 29: 7–13.
59.
KrzyżekPGościniakG. Immunomodulatory influence of HIV and EBV on Helicobacter pylori infections – a review. Ann Parasitol2019; 65: 3–17.
60.
NkuizeMDe WitSDemetterP, et al.Helicobacter pylori and human immunodeficiency virus co-infection: potential implications for future gastric cancer risk. Microorganisms2023; 11: 887.
61.
OkameMTakayaSSatoH, et al.Complete regression of early-stage gastric diffuse large B-cell lymphoma in an HIV-1-infected patient following Helicobacter pylori eradication therapy. Clin Infect Dis2014; 58: 1490–1492.
62.
SheltonMJAkbariBHewittRG, et al.Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. J Acquir Immune Defic Syndr2000; 24: 79–82.
63.
BrenchleyJMPriceDASchackerTW, et al.Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med2006; 12: 1365–1371.
64.
HestvikETylleskarTNdeeziG, et al.Prevalence of Helicobacter pylori in HIV-infected, HAART-naïve Ugandan children: a hospital-based survey. J Int AIDS Soc2011; 14: 34.
65.
Radovanović SpurnićABrmbolićBStojšićZ, et al.The increasing prevalence of HIV/Helicobacter pylori co-infection over time, along with the evolution of antiretroviral therapy (ART). PeerJ2017; 5: e3392.
66.
Longo-MbenzaBApalataTLongokoloM, et al.Association of Helicobacter pylori infection with the metabolic syndrome among HIV-infected black Africans receiving highly active antiretroviral therapy. Cardiovasc J Afr2015; 26: 52–56.
67.
SousaAEChavesAFDoroanaM, et al.Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection. J Immunol1999; 162: 3718–3726.
68.
RibeiroJMLucasMPalhanoMJ, et al.Remission of a high-grade gastric mucosa associated lymphoid tissue (MALT) lymphoma following Helicobacter pylori eradication and highly active antiretroviral therapy in a patient with AIDS. Am J Med2001; 111: 328–329.
69.
NachegaJBHsuAJUthmanOA, et al.Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS2012; 26: S39–S53.
70.
StolbachAPazianaKHeverlingH, et al.A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol2015; 11: 326–341.
KakudaTNWoodfallBDe MarezT, et al.Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. J Antimicrob Chemother2014; 69: 728–734.
78.
SekarVJSpinosa-GuzmanSDe PaepeE, et al.Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol2008; 48: 60–65.
NkuizeMVanderpasJBusetM, et al.Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: a descriptive observational study. Microbiologyopen2021; 10: e1184.
81.
ThungIAraminHVavinskayaV, et al.Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther2016; 43: 514–533.
82.
ButcherLDden HartogGErnstPB, et al.Oxidative stress resulting from Helicobacter pylori infection contributes to gastric carcinogenesis. Cell Mol Gastroenterol Hepatol2017; 3: 316–322.
83.
LinEAZhangXSLevineSM, et al.Natural transformation of helicobacter pylori involves the integration of short DNA fragments interrupted by gaps of variable size. PLoS Pathog2009; 5: e1000337.
84.
NkuizeMVanderpasJBusetM, et al.Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med2021; 22: 547–556.
85.
NkuizeMDe WitSMulsV, et al.HIV-Helicobacter pylori co-infection: antibiotic resistance, prevalence, and risk factors. PLoS One2015; 10: e0145119.
86.
MalfertheinerPMegraudFO'MorainCA, et al.Management of Helicobacter pylori infection-the Maastricht V/florence consensus report. Gut2017; 66: 6–30.
87.
PeroRBrancaccioMLaneriS, et al.A novel view of human Helicobacter pylori infections: interplay between Microbiota and Beta-Defensins. Biomolecules2019; 9: 237.
88.
ScarpelliniPCarreraPCavalleroA, et al.Direct detection of Helicobacter pylori mutations associated with macrolide resistance in gastric biopsy material taken from human immunodeficiency virus-infected subjects. J Clin Microbiol2002; 40: 2234–2237.
89.
MesfunMGGligaSFuchsA, et al.Prevalence of H. pylori among asymptomatic HIV-positive and negative individuals in Central Ethiopia and efficacy of eradication therapy. IJID Reg2022; 2: 169–174.
